330 related articles for article (PubMed ID: 27099271)
21. First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement.
Thompson IM; Albanes D; Basler JW; Crawford ED; Denis LJ; Djavan B; Fleshner N; Johnson-Pais TL; Klein EA; Kristal AR; Lucia MS; Parnes HL; Piazza GA; Platz EA; Pollock BH; Price DK; Reichardt JK; Tangen CM; Tolcher AW; McMann MC
J Urol; 2004 Feb; 171(2 Pt 2):S3-4. PubMed ID: 14713744
[No Abstract] [Full Text] [Related]
22. Cancer chemoprevention drug targets.
Krishnan K; Campbell S; Abdel-Rahman F; Whaley S; Stone WL
Curr Drug Targets; 2003 Jan; 4(1):45-54. PubMed ID: 12528989
[TBL] [Abstract][Full Text] [Related]
23. High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research.
Marshall JR
IARC Sci Publ; 2001; 154():191-8. PubMed ID: 11220658
[TBL] [Abstract][Full Text] [Related]
24. Target populations and strategies for chemoprevention trials of prostate cancer.
Bostwick DG
J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591
[TBL] [Abstract][Full Text] [Related]
25. Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer.
Thompson IM; Basler JA; Leach R; Troyer D; Klein E; Brawley O
Urol Oncol; 2003; 21(1):73-8. PubMed ID: 12684131
[TBL] [Abstract][Full Text] [Related]
26. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer prevention: what do we know now and when will we know more?
Thompson IM; Basler J; Hensley D; von Merveldt D; Jenkins CA; Higgins B; Leach R; Troyer D; Pollock B
Clin Prostate Cancer; 2003 Mar; 1(4):215-20. PubMed ID: 15040879
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer prevention trials in the USA.
Brawley OW; Parnes H
Eur J Cancer; 2000 Jun; 36(10):1312-5. PubMed ID: 10882873
[TBL] [Abstract][Full Text] [Related]
29. Selenium and prostate cancer prevention.
Nelson MA; Porterfield BW; Jacobs ET; Clark LC
Semin Urol Oncol; 1999 May; 17(2):91-6. PubMed ID: 10332922
[TBL] [Abstract][Full Text] [Related]
30. Introductory remarks: development of chemopreventive agents for prostate cancer.
Kelloff GJ; Boone CW; Malone WF; Steele VE; Doody LA
J Cell Biochem Suppl; 1992; 16H():1-8. PubMed ID: 1289663
[TBL] [Abstract][Full Text] [Related]
31. Chemoprevention of cancer.
Szarka CE; Grana G; Engstrom PF
Curr Probl Cancer; 1994; 18(1):6-79. PubMed ID: 8005001
[TBL] [Abstract][Full Text] [Related]
32. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer chemoprevention: an overview of United States trials.
Barqawi A; Thompson IM; Crawford ED
J Urol; 2004 Feb; 171(2 Pt 2):S5-8; discussion S9. PubMed ID: 14713745
[TBL] [Abstract][Full Text] [Related]
34. Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.
Lü J; Zhang J; Jiang C; Deng Y; Özten N; Bosland MC
Nutr Cancer; 2016; 68(1):1-17. PubMed ID: 26595411
[TBL] [Abstract][Full Text] [Related]
35. Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings.
Meuillet E; Stratton S; Prasad Cherukuri D; Goulet AC; Kagey J; Porterfield B; Nelson MA
J Cell Biochem; 2004 Feb; 91(3):443-58. PubMed ID: 14755676
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents.
Nelson WG; Wilding G
Urology; 2001 Apr; 57(4 Suppl 1):56-63. PubMed ID: 11295596
[TBL] [Abstract][Full Text] [Related]
37. Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials.
Trock BJ
Urology; 2001 Apr; 57(4 Suppl 1):241-7. PubMed ID: 11295636
[TBL] [Abstract][Full Text] [Related]
38. New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents.
Williams ED; Brooks JD
Urology; 2001 Apr; 57(4 Suppl 1):100-2. PubMed ID: 11295605
[TBL] [Abstract][Full Text] [Related]
39. Design considerations for efficient prostate cancer chemoprevention trials.
Lee JJ; Lieberman R; Sloan JA; Piantadosi S; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):205-12. PubMed ID: 11295629
[TBL] [Abstract][Full Text] [Related]
40. The role of molecular genetics in chemoprevention studies of prostate cancer.
Ross RK
IARC Sci Publ; 2001; 154():207-13. PubMed ID: 11220660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
